A phase I study of bevacizumab (BV) plus ABT-510 in patients with advanced solid tumors

被引：0
|
作者：
Uronis, H. E. [1 ]
Bendell, J. [1 ]
Blobe, G. [1 ]
Morse, M. [1 ]
Geier, D. [1 ]
Nixon, A. [1 ]
Howard, L. [1 ]
Evans, D. [1 ]
Li, H. [1 ]
Hurwitz, H. [1 ]
机构：
[1] Duke Univ, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3541
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma
    Ebbinghaus, SW
    Hussain, M
    Tannir, NM
    Gordon, MS
    Desai, AA
    Knight, RA
    Carlson, DM
    Figlin, RA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 404S - 404S
  • [32] A Phase I Study of Sunitinib plus Bevacizumab in Advanced Solid Tumors (vol 15, pg 6277, 2009)
    Dowlati, Afshin
    CLINICAL CANCER RESEARCH, 2009, 15 (24) : 7751 - 7751
  • [33] A phase I study of brostallicin (B) combined with either bevacizumab (BV) or irinotecan (I) in patients (pts) with advanced solid malignancies
    MacArthur, R. B.
    Singer, J.
    Becerra, C.
    Weitman, S.
    Von Hoff, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Rangwala, Fatima
    Bendell, Johanna C.
    Kozloff, Mark F.
    Arrowood, Christy C.
    Dellinger, Andrew
    Meadows, Jennifer
    Tourt-Uhlig, Sandra
    Murphy, Jennifer
    Meadows, Kellen L.
    Starr, Aijing
    Broderick, Samuel
    Brady, John C.
    Cushman, Stephanie M.
    Morse, Michael A.
    Uronis, Hope E.
    Hsu, S. David
    Zafar, S. Yousuf
    Wallace, James
    Starodub, Alexander N.
    Strickler, John H.
    Pang, Herbert
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (04) : 700 - 709
  • [35] Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors
    Fatima Rangwala
    Johanna C. Bendell
    Mark F. Kozloff
    Christy C. Arrowood
    Andrew Dellinger
    Jennifer Meadows
    Sandra Tourt-Uhlig
    Jennifer Murphy
    Kellen L. Meadows
    Aijing Starr
    Samuel Broderick
    John C. Brady
    Stephanie M. Cushman
    Michael A. Morse
    Hope E. Uronis
    S. David Hsu
    S. Yousuf Zafar
    James Wallace
    Alexander N. Starodub
    John H. Strickler
    Herbert Pang
    Andrew B. Nixon
    Herbert I. Hurwitz
    Investigational New Drugs, 2014, 32 : 700 - 709
  • [36] Sunitinib and bevacizumab in advanced solid tumors: A phase I trial
    Cooney, M. M.
    Garcia, J. A.
    Elson, P.
    Mekhail, T.
    Dreicer, R.
    Nock, C. J.
    Bokar, J. A.
    Tyler, A.
    Beatty, K.
    Bukowski, R. M.
    Rini, B. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [37] Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors
    Varghese, Anna M.
    Cardin, Dana B.
    Hersch, Jonathan
    Benson, Al B.
    Hochster, Howard S.
    Makris, Lukas
    Hamada, Kensuke
    Berlin, Jordan D.
    Saltz, Leonard B.
    CLINICAL CANCER RESEARCH, 2020, 26 (07) : 1555 - 1562
  • [38] Phase I study of paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors
    Schultheis, B.
    Neumann, H.
    Roy, R.
    Kummer, G.
    Strumberg, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [39] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Emiliano Calvo
    Cristiana Sessa
    Guilherme Harada
    Maria de Miguel
    Carmen Kahatt
    Xarles Erik Luepke-Estefan
    Mariano Siguero
    Carlos Fernandez-Teruel
    Martin Cullell-Young
    Anastasios Stathis
    Alexander Drilon
    Investigational New Drugs, 2022, 40 : 1263 - 1273
  • [40] Phase I study of lurbinectedin in combination with weekly paclitaxel with or without bevacizumab in patients with advanced solid tumors
    Calvo, Emiliano
    Sessa, Cristiana
    Harada, Guilherme
    de Miguel, Maria
    Kahatt, Carmen
    Luepke-Estefan, Xarles Erik
    Siguero, Mariano
    Fernandez-Teruel, Carlos
    Cullell-Young, Martin
    Stathis, Anastasios
    Drilon, Alexander
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (06) : 1263 - 1273
12345